Cost-effectiveness of a 12-month fixed-duration venetoclax treatment in combination with obinutuzumab in first-line, unfit chronic lymphocytic leukemia in the United StatesAnuja Chatterjee, Matthew S. Davids, Kavita Sail et al.|Journal of Managed Care & Specialty Pharmacy|2021Cited by 20